Safety and tolerability of conditioning chemotherapy followed by CD19-targeted CAR T cells for relapsed/refractory CLL

BACKGROUND: Subgroups of patients with relapsed or refractory (R/R) chronic lymphocytic leukemia (CLL) exhibit suboptimal outcomes after standard therapies, including oral kinase inhibitors. We and others have previously reported on the safety and efficacy of autologous CD19-targeted CAR T cells for...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:JCI Insight
Autori principali: Geyer, Mark B., Rivière, Isabelle, Sénéchal, Brigitte, Wang, Xiuyan, Wang, Yongzeng, Purdon, Terence J., Hsu, Meier, Devlin, Sean M., Palomba, M. Lia, Halton, Elizabeth, Bernal, Yvette, van Leeuwen, Dayenne G., Sadelain, Michel, Park, Jae H., Brentjens, Renier J.
Natura: Artigo
Lingua:Inglês
Pubblicazione: American Society for Clinical Investigation 2019
Soggetti:
Clinical Medicine
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6538317/
https://ncbi.nlm.nih.gov/pubmed/30938714
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/jci.insight.122627
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi